Insertion/deletion polymorphism of angiotensin I converting enzyme gene and left ventricular hypertrophy in patients with type 2 diabetes mellitus

Kardiologia Polska

Volumn 64, Issue 9, 2006, Pages 959-965

  Molȩda, Piotr ^a   Majkowska, Liliana ^a   Kaliszczak, Robert ^a   Safranow, Krzysztof ^a   Adler, Grazyna ^a   Gora̧cy, Iwona ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

ACE; Genetics; Left ventricular hypertrophy; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; ECHOCARDIOGRAPHY; FEMALE; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION;

EID: 33750050287     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pasierski T, Grodzicki T. Nadciśnieniowa choroba serca. Medycyna Praktyczna, Kraków 1999; 12-3.
2. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Eng J Med 1990; 322: 1561-6.
3. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-8.
4. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-6.
5. Post WS, Levy D. New developments in the epidemiology of left ventricular hypertrophy. Curr Opin Cardiol 1994; 9: 534-41.
6. Kowalska I, Telejko B, Kinalska I. Leczenie cukrzycy a choroba niedokrwienna serca. Terapia 2002; 5: 29-33.
7. Galderisi M, Anderson KM, Wilson PW, et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-9.
8. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
9. Marre M. Association between angiotensin I converting enzyme gene polymorphism, plasma levels and diabetic nephropathy. Diabetologia 1993; 36 (Suppl. 1): 127.
10. Marre M, Bernadet P, Gallois Y, et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-8.
11. Dorecka M, Grzeszczak W, Romaniuk W, et al. Polimorfizm insercja/delecja genu enzymu konwertuja̧cego angiotensynȩ I (ACE I) oraz polimorfizm Pstl ograniczonego łańcucha genu ACE w intronie 7 a rozwój retinopatii u chorych z cukrzyca̧ typu 2. Diabetologia Pol 2001; 1: 1-9.
12. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-8.
13. Iwai N, Shimoike H, Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995; 92: 2690-6.
14. Kuznetsova T, Staessen JA, Wang JG, et al. Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J Hum Hypertens 2000; 14: 447-54.
15. Kupari M, Perola M, Koskinen P, et al. Left ventricular size, mass, and function in relation to angiotensin-converting enzyme gene polymorphism in humans. Am J Physiol 1994; 267: H1107-11.
16. Celentano A, Mancini FP, Crivaro M, et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83: 1196-200.
17. Czarnecka D, Kawecka-Jaszcz K, Stolarz K, et al. Genetic factors in hypertension. Angiotensin-converting enzyme polymorphism. Kardiol Pol 2004; 61: 1-10.
18. Estacio RO, Jeffers BW, Havranek EP, et al. Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Am J Hypertens 1999; 12: 637-42.
19. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
20. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59: 956-60.
21. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
22. de Simone G, Palmieri V, Koren MJ, et al. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens 2001; 19: 119-25.
23. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-11.
24. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273: 1592-7.
25. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005; 48: 1971-9.
26. Nakahara K, Matsushita S, Matsuoka H, et al. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene affects heart weight. Circulation 2000; 101: 148-51.
27. Lindpaintner K, Lee M, Larson MG, et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 1996; 334: 1023-8.
28. Gruchala M, Ciecwierz D, Ochman K, et al. Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease. Clin Chem Lab Med 2003; 41: 522-8.